Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Subscribe To Our Newsletter & Stay Updated
